Previous studies showed that RTEF-1 as a downstream effector of the Hippo pathway has important roles in cancer, including epithelial–mesenchymal transition (EMT), metastasis, cancer stem cell dynamics, and chemotherapeutic drug resistance, suggesting that RTEF-1 may be a promising prognostic biomarker in cancer [9]. This evidence concerns the gene TEAD4 and cancer.